Fresenius | FRE - Selling And Administration Expenses


Fresenius reported EUR743M in Selling and Administration Expenses for its fiscal quarter ending in March of 2026.





Selling And Administration Expenses Change Date
Akzo Nobel EUR 833M 29M Jun/2026
Alcon AG USD 882M 19M Mar/2026
AstraZeneca USD 5.8B 735M Jun/2026
BASF EUR 2.28B 156M Jun/2026
Bayer EUR 3.7B 356M Mar/2026
Beiersdorf EUR 271M 51M Dec/2025
DaVita Healthcare Partners USD 421.91M 50.45M Mar/2026
Demant DKK 6.09B 135M Dec/2025
E.ON EUR -1.71B 3.63B Jun/2025
Essilor EUR 5.75B 139M Jun/2026
Fresenius EUR 743M 76M Mar/2026
Fresenius Medical Care EUR 749M 36M Mar/2026
Getinge SEK 2.65B 452M Dec/2024
Givaudan CHF 561M 25M Dec/2025
GlaxoSmithKline GBP 2.19B 75M Jun/2026
GN Store Nord DKK 763M 688M Mar/2026
GRIFOLS EUR 289M 8M Jun/2026
Hikma Pharmaceutical USD 288M 149M Dec/2025
Merck EUR 1.52B 80M Mar/2026
Novartis USD 3.24B 101M Jun/2026
Philips EUR 1.21B 23M Jun/2026
Roche Holding CHF 6.37B 908M Jun/2026
RWE EUR 690M 84M Mar/2025
Sanofi EUR 2.63B 307M Jun/2026
Smith & Nephew USD 1.45B 29M Jun/2026